Insider Selling: Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells 13,400 Shares of Stock

by · The Cerbat Gem

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CFO Dominic Piscitelli sold 13,400 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $13.53, for a total transaction of $181,302.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at $944,772.84. This represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dominic Piscitelli also recently made the following trade(s):

  • On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total transaction of $8,100.00.
  • On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00.

Oric Pharmaceuticals Price Performance

ORIC stock traded up $0.10 during trading on Tuesday, hitting $13.37. 977,261 shares of the company traded hands, compared to its average volume of 1,402,947. The company has a market cap of $1.39 billion, a PE ratio of -9.90 and a beta of 1.00. The stock’s 50-day simple moving average is $12.89 and its 200 day simple moving average is $10.85. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). Research analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Oric Pharmaceuticals in the 2nd quarter valued at $73,904,000. Siren L.L.C. raised its holdings in shares of Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after acquiring an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Oric Pharmaceuticals by 19.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after acquiring an additional 244,060 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Oric Pharmaceuticals by 105.5% during the 1st quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock valued at $13,217,000 after acquiring an additional 535,649 shares during the last quarter. Finally, Algert Global LLC grew its holdings in shares of Oric Pharmaceuticals by 791.3% in the second quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock valued at $13,162,000 after purchasing an additional 1,078,943 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ORIC shares. HC Wainwright increased their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Stifel Nicolaus started coverage on Oric Pharmaceuticals in a research note on Friday, June 12th. They issued a “buy” rating and a $14.00 price target on the stock. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Finally, Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $20.18.

Get Our Latest Stock Report on Oric Pharmaceuticals

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.

Oric’s research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).

Read More